Immunomodulation in myelodysplastic syndromes

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 4, 2006, Pages 757-767

  Sekeres, Mikkael A ^a   List, Alan ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

immunomodulation; myelodysplastic syndromes; outcome; treatment

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; CHLORAMBUCIL; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOMODULATING AGENT; INFLIXIMAB; LENALIDOMIDE; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SCIO 469; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BLEEDING; BLOOD ANALYSIS; BONE MARROW CELL; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL CYCLE ARREST; CELL MATURATION; CLINICAL TRIAL; CONSTIPATION; CYTOKINE PRODUCTION; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GENE FUNCTION; GENE MUTATION; GENETIC CODE; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; INFECTION; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RECEPTOR BLOCKING; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; RISK FACTOR; SECOND CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; URTICARIA;

HUMANS; IMMUNOLOGIC FACTORS; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 33748706143     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.06.001     Document Type: Review

References (36)

1. List A.F., Vardiman J., Issa J.P., and DeWitte T.M. Myelodysplastic syndromes. Hematology (American Society of Hematology Education Program) (2004) 297-317
2. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 10 12 (1999) 1419-1432
3. Aul C., Gattermann N., and Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. British Journal of Haematology 82 2 (1992) 358-367
4. Williamson P.J., Kruger A.R., Reynolds P.J., Hamblin T.J., and Oscier D.G. Establishing the incidence of myelodysplastic syndrome. British Journal of Haematology 87 4 (1994) 743-745
5. Paul B., Reid M.M., Davison E.V., Abela M., and Hamilton P.J. Familial myelodysplasia: progressive disease associated with emergency of monosomy 7. British Journal of Haematology 65 3 (1987) 321-323
6. Pasqualetti P., Casale R., Colantonio D., and Collacciani A. Occupational risk for hematological malignancies. American Journal of Hematology 38 2 (1991) 147-149
7. Karp J.E., and Smith M.A. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Seminars in Oncology 24 1 (1997) 103-113
8. Allampallam K., Shetty V., Mundle S., Dutt D., Kravitz H., Reddy P.L., et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. International Journal of Hematology 75 3 (2002) 289-297
9. Bellamy W.T., Richter L., Sirjani D., Roxas C., Glinsmann-Gibson B., Frutiger Y., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97 5 (2001) 1427-1434
10. Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 11 12 (1997) 2049-2054
11. Schipperus M., Sonneveld P., Lindemans J., Hagemeijer A., Vink N., Pegels J., et al. The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 4 4 (1990) 267-272
12. Sugimoto K., Hirano N., Toyoshima H., Chiba S., Mano H., Takaku F., et al. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81 11 (1993) 3022-3026
13. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology 51 2 (1982) 189-199
14. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
15. Haase D., Steidl C., Schanz J., Schabla R., Pfeilstöcker M., Nösslinger T., et al. Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS. Blood 106 (2005) 232a
16. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
17. Malcovati L., Germing U., Kuendgen A., Porta M.D., Invernizzi R., Giagounidis A., et al. A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes. Blood 106 (2005) 232a
18. Hellstrom-Lindberg E., Negrin R., Stein R., Krantz S., Lindberg G., Vardiman J., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. British Journal of Haematology 99 2 (1997) 344-351
19. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology 120 6 (2003) 1037-1046
20. Corral L.G., and Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Annals of the Rheumatic Diseases 58 supplement 1 (1999) I107-I113
21. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 1 (2001) 210-216
22. Geitz H., Handt S., and Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31 2-3 (1996) 213-221
23. Parman T., Wiley M.J., and Wells P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Medicine 5 5 (1999) 582-585
24. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 4 (2001) 958-965
25. Cheson B.D., Bennett J.M., Kantarjian H., Schiffer C.A., Nimer S.D., Lowenberg B., et al. Myelodysplastic syndromes standardized response criteria: further definition. Blood 98 6 (2001) 1985
26. Musto P., Falcone A., Sanpaolo G., Bisceglia M., Matera R., Carella A.M., et al. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica 87 8 (2002) 884-886
27. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., and Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 16 1 (2002) 1-6
28. Morena-Aspitia A., Geyer S., Li C.-Y., et al. N998B: multicenter phase II trial of thalidomide (thal) in adult patients with myelodysplastic syndromes (MDS). Blood 100 (2002) 96a
29. List A., Tate W., and Glinsmann-Gibson B. The immunomodulatory thalidomide analog, CC-5013, inhibits tropic response in VEGF in AML cells by abolishing cytokine-induced PI3/Akt activation. Blood 100 (2002) 139a
30. List A., Kurtin S., Roe D., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of Lenalidomide in Myelodysplastic Syndromes. The New England Journal of Medicine 352 (2005)
31. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96 12 (2000) 3671-3674
32. Buesche G., Dieck S., Giagounidis A., Bock O., Wilkens L., Schlegelberger B., et al. Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease. Blood 106 (2005) 113a
33. List A., Dewald G., Bennett J., Giagounadis A., Raza A., Feldman E., et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 study. Journal of Clinical Oncology (Proceedings of the American Society of Clinical Oncology) 23 (2005) 2s
34. Raza A., Candoni A., Khan U., Lisak L., Tahir S., Silvestri F., et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leukemia & Lymphoma 45 10 (2004) 2099-2104
35. Salituro F.G., Germann U.A., Wilson K.P., Bemis G.W., Fox T., and Su M.S. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Current Medicinal Chemistry 6 9 (1999) 807-823
36. Saarni M.I., and Linman J.W. Preleukemia. The hematologic syndrome preceding acute leukemia. The American Journal of Medicine 55 1 (1973) 38-48